PHASE I MULTIPLE DOSE, DOSE ESCLATION TRIAL OF MDL 101,731

目标是：1)确定最大容许剂量水平(MTD)和 相应的静息期；2)表征剂量限制毒性 (DLT)；3)表征血浆和尿药动学/ 药效学；4)记录抗肿瘤活性的证据 可行；以及5)使用核磁共振，测试MDL 101,731及其 血浆、尿液和组织中的含氟代谢物 可行。估计最多将有40名成人患者入选。 患者将患有没有标准治疗的晚期实体恶性肿瘤 根治疗法是存在的。他们要么天真，要么顽固地 治疗(药物治疗和放射治疗)。

Objectives are: 1) determine the maximum tolerated dose level (MTD) and corresponding rest period; 2) characterize the dose-limiting toxicities (DLT); 3) characterize plasma and urine pharmacokinetics/ pharmacodynamics; 4) document evidence of antitumor activity when feasible; and 5) using NMR, test for the presence of MDL 101,731 and its flourinated metabolites in plasma and urine and in tissues when feasible. An estimated maximum of 40 adult patients will be enrolled. Patients will have advanced solid malignancies for which no standard curative therapy exists. They will be either naive or refractory to treatment (medication and radiation).